The startup develops breath diagnostic products that utilize gas chromatography and mass spectrometry for at-home testing, enabling early detection of diseases such as influenza, COVID-19, and various cancers. By providing rapid, non-invasive diagnostics directly to patients, the company addresses the need for timely health assessments and disease monitoring in the healthcare sector.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional diagnostic methods for diseases like influenza, COVID-19, and cancer often require invasive procedures or laboratory analysis, leading to delays in diagnosis and treatment. The need for frequent testing and monitoring, especially for individuals at high risk or in remote locations, presents logistical challenges and limits accessibility to timely healthcare.
Solution
The startup is developing breath diagnostic products that leverage gas chromatography and mass spectrometry to enable convenient and non-invasive at-home testing. This approach allows for rapid detection of diseases such as influenza, COVID-19, and various cancers directly by the patient. By providing a user-friendly and accessible diagnostic tool, the company aims to facilitate early disease detection, improve patient outcomes, and reduce the burden on healthcare systems. The technology offers a potential solution for frequent monitoring and timely health assessments, particularly in situations where traditional methods are impractical or inaccessible.
Target Audience
The primary target audience includes individuals at high risk for infectious diseases or cancer, healthcare providers seeking rapid diagnostic tools, and organizations involved in remote patient monitoring and telehealth services.
Features
- Breath-based diagnostic testing for early disease detection.
- Utilizes gas chromatography and mass spectrometry for accurate analysis.
- Non-invasive and convenient at-home testing procedure.
- Rapid results for timely health assessments.
- Potential for frequent monitoring of high-risk individuals.